Alzheimer's Society blog

Trontinemab is one of the latest disease-modifying drugs currently being tested in late-stage clinical trials. Here’s what we know about this potential new treatment for Alzheimer's disease.

An innovative sensor that measures changes in the properties of light – and which is the size of a postage stamp – could help improve how Alzheimer’s disease is detected in the future. 

Alzheimer’s Society responds to Cochrane review of ‘Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer’s disease’ - April 2026.

We described 2024 as the biggest year for dementia research yet - and now, 2025 has proved to be just as impactful.

Semaglutide (the essential ingredient in Rybelsus, Ozempic and Wegovy) is currently in the headlines after the disappointing news that clinical trials showed it does not help slow Alzheimer’s disease. Here’s what we know about this drug. 

In the laboratory, dementia researchers focus on understanding how sickness in the brain can lead to loss of memory and identity. Over many studies, a few key proteins have stood out as having a significant role, and one of them is tau.